Mechanisms of mineralocorticoid salt-induced hypertension and cardiac fibrosis

Molecular and Cellular Endocrinology

Volumn 350, Issue 2, 2012, Pages 248-255

  Young, Morag J ^a   Rickard, Amanda J ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

Author keywords

Aldosterone; Cardiac fibrosis; Corticosterone; Macrophage; Mineralocorticoid receptor; Oxidative stress

Indexed keywords

GELATINASE A; GELATINASE B; MESSENGER RNA; MINERALOCORTICOID RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1;

CARDIOVASCULAR RESPONSE; CELL TYPE; DISEASE COURSE; FIBROBLAST; GENE TARGETING; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; HYPERTENSION; ION TRANSPORT; MYOFIBROBLAST; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

ANIMALS; CARDIOVASCULAR SYSTEM; ENDOMYOCARDIAL FIBROSIS; HUMANS; HYPERTENSION; INFLAMMATION; MODELS, BIOLOGICAL; RECEPTORS, MINERALOCORTICOID; SIGNAL TRANSDUCTION; SODIUM, DIETARY;

EID: 84856346254     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2011.09.008     Document Type: Review

References (132)

1. 2 in peripheral blood mononuclear cells. Circulation 2005, 111(1):51-57.
2. Armanini D., Strasser T., Weber P.C. Characterization of aldosterone binding sites in circulating human mononuclear leukocytes. Am J Physiol 1985, 248(3 Pt 1):E388-E390.
3. Arriza J.L., et al. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 1987, 237(4812):268-275.
4. Barnett C.A., Pritchett E.L. Detection of corticosteroid type I binding sites in heart. Mol. Cell. Endocrinol. 1988, 56(3):191-198.
5. Bayorh M.A., et al. Alterations in aldosterone and angiotensin II levels in salt-induced hypertension. Clin. Exp. Hypertens. 2005, 27(4):355-367.
6. Berecek K.H., Bohr D.F. Whole body vascular reactivity during the development of deoxycorticosterone acetate hypertension in the pig. Circ. Res. 1978, 42(6):764-771.
7. + metabolism. Kidney Int. 2000, 57(4):1295-1298.
8. Bleich M., et al. Rescue of the mineralocorticoid receptor knock-out mouse. Pflugers Arch. 1999, 438(3):245-254.
9. Bohr D.F. What makes the pressure go up? A hypothesis. Hypertension 1981, 3(6 Pt 2):II160-II165.
10. Brilla C.G., Weber K.T. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J. Lab. Clin. Med. 1992, 120(6):893-901.
11. Brown L., et al. Reversal of cardiac fibrosis in deoxycorticosterone acetate-salt hypertensive rats by inhibition of the renin-angiotensin system. J. Am. Soc. Nephrol. 1999, 10(Suppl. 11):S143-S148.
12. Callera G.E., et al. ETA receptor mediates altered leukocyte-endothelial cell interaction and adhesion molecules expression in DOCA-salt rats. Hypertension 2004, 43(4):872-879.
13. Calo L.A., et al. Effect of aldosterone and glycyrrhetinic acid on the protein expression of PAI-1 and p22(phox) in human mononuclear leukocytes. J. Clin. Endocrinol. Metab. 2004, 89(4):1973-1976.
14. Campbell S.E., Janicki J.S., Weber K.T. Temporal differences in fibroblast proliferation and phenotype expression in response to chronic administration of angiotensin II or aldosterone. J. Mol. Cell. Cardiol. 1995, 27(8):1545-1560.
15. Chen X., et al. Antioxidant effects of vitamins C and E are associated with altered activation of vascular NADPH oxidase and superoxide dismutase in stroke-prone SHR. Hypertension 2001, 38(3 Pt 2):606-611.
16. Christy C., et al. 11beta-hydroxysteroid dehydrogenase type 2 in mouse aorta: localization and influence on response to glucocorticoids. Hypertension 2003, 42(4):580-587.
17. Chun T.Y., Bloem L.J., Pratt J.H. Aldosterone inhibits inducible nitric oxide synthase in neonatal rat cardiomyocytes. Endocrinology 2003, 144(5):1712-1717.
18. Connell J.M., et al. A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function. Endocr. Rev. 2008, 29(2):133-154.
19. Cosentino F., Luscher T.F. Tetrahydrobiopterin and endothelial function. Eur. Heart J. 1998, 19(Suppl. G):G3-G8.
20. Dewald O., et al. CCL2/monocyte chemoattractant protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circ. Res. 2005, 96(8):881-889.
21. Doi T., et al. Aldosterone induces interleukin-18 through endothelin-1, angiotensin II, Rho/Rho-kinase, and PPARs in cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol. 2008, 295(3):H1279-H1287.
22. Duprez D.A., et al. Influence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension. Am. J. Cardiol. 1993, 71(3):17A-20A.
23. Edwards C.R., et al. Localisation of 11 beta-hydroxysteroid dehydrogenase - tissue specific protector of the mineralocorticoid receptor. Lancet 1988, 2(8618):986-989.
24. Eghbali M., Weber K.T. Collagen and the myocardium: fibrillar structure, biosynthesis and degradation in relation to hypertrophy and its regression. Mol. Cell. Biochem. 1990, 96(1):1-14.
25. Elmarakby A.A., et al. TNF-alpha inhibition reduces renal injury in DOCA-salt hypertensive rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2008, 294(1):R76-R83.
26. Fan Y.Y., et al. Augmentation of intrarenal angiotensin II levels in uninephrectomized aldosterone/salt-treated hypertensive rats; renoprotective effects of an ultrahigh dose of olmesartan. Hypertens. Res. 2006, 29(3):169-178.
27. Fejes-Toth G., Naray-Fejes-Toth A. Early aldosterone-regulated genes in cardiomyocytes: clues to cardiac remodeling?. Endocrinology 2007, 148(4):1502-1510.
28. Fraccarollo D., et al. Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation 2011, 123(4):400-408.
29. Fraccarollo D., et al. Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation 2011, 123:400-408.
30. Fujisawa G., et al. Experimental cardiac fibrosis: differential time course of responses to mineralocorticoid-salt administration. Endocrinology 2001, 142(8):3625-3631.
31. Funder J.W. Corticosteroid receptors and renal 11 beta-hydroxysteroid dehydrogenase activity. Semin. Nephrol. 1990, 10(4):311-319.
32. Funder J.W. Is aldosterone bad for the heart?. Trends Endocrinol. Metab. 2004, 15(4):139-142.
33. Funder J.W. RALES, EPHESUS and redox. J. Steroid Biochem. Mol. Biol. 2005, 93(2-5):121-125.
34. Funder J.W., et al. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 1988, 242(4878):583-585.
35. Garwitz E.T., Jones A.W. Altered arterial ion transport and its reversal in aldosterone hypertensive rat. Am. J. Physiol. 1982, 243(6):H927-H933.
36. Geerling J.C., Kawata M., Loewy A.D. Aldosterone-sensitive neurons in the rat central nervous system. J. Comp. Neurol. 2006, 494(3):515-527.
37. Geerling J.C., et al. Aldosterone target neurons in the nucleus tractus solitarius drive sodium appetite. J. Neurosci. 2006, 26(2):411-417.
38. Gerling I.C., et al. Aldosteronism: an immunostimulatory state precedes proinflammatory/fibrogenic cardiac phenotype. Am. J. Physiol. Heart Circ. Physiol. 2003, 285(2):H813-H821.
39. Gomez-Sanchez E.P., et al. ICV infusion of corticosterone antagonizes ICV-aldosterone hypertension. Am J Physiol 1990, 258(4 Pt 1):E649-E653.
40. Gomez-Sanchez E.P., Fort C., Thwaites D. Central mineralocorticoid receptor antagonism blocks hypertension in Dahl S/JR rats. Am. J. Physiol. 1992, 262(1 Pt 2):E96-E99.
41. Goto A., et al. Effect of an anteroventral third ventricle lesion on NaCl hypertension in Dahl salt-sensitive rats. Am. J. Physiol. 1982, 243(4):H614-H618.
42. Guzik T.J., et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J. Exp. Med. 2007, 204(10):2449-2460.
43. Harada E., et al. Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes. Circulation 2001, 104(2):137-139.
44. Heitzer T., et al. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001, 104(22):2673-2678.
45. Herman J.P., et al. Localization and regulation of glucocorticoid and mineralocorticoid receptor messenger RNAs in the hippocampal formation of the rat. Mol. Endocrinol. 1989, 3(11):1886-1894.
46. Hewitt K.N., Walker E.A., Stewart P.M. Minireview: hexose-6-phosphate dehydrogenase and redox control of 11{beta}-hydroxysteroid dehydrogenase type 1 activity. Endocrinology 2005, 146(6):2539-2543.
47. Hirono Y., et al. Angiotensin II receptor type 1-mediated vascular oxidative stress and proinflammatory gene expression in aldosterone-induced hypertension: the possible role of local renin-angiotensin system. Endocrinology 2007, 148(4):1688-1696.
48. Ishimaru K., et al. Fasudil attenuates myocardial fibrosis in association with inhibition of monocyte/macrophage infiltration in the heart of DOCA/salt hypertensive rats. J. Cardiovasc. Pharmacol. 2007, 50(2):187-194.
49. Jaffe I.Z., Mendelsohn M.E. Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ. Res. 2005, 96(6):643-650.
50. Johar S., et al. Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. FASEB J. 2006, 20(9):1546-1548.
51. Ko E.A., et al. Resistance artery remodeling in deoxycorticosterone acetate-salt hypertension is dependent on vascular inflammation: evidence from m-CSF-deficient mice. Am. J. Physiol. Heart Circ. Physiol. 2007, 292(4):H1789-H1795.
52. Kohler E., et al. Does aldosterone-induced cardiac fibrosis involve direct effects on cardiac fibroblasts?. J. Vasc. Res. 1996, 33(4):315-326.
53. Krozowski Z.S., Funder J.W. Renal mineralocorticoid receptors and hippocampal corticosterone-binding species have identical intrinsic steroid specificity. Proc Natl Acad Sci USA 1983, 80(19):6056-6060.
54. Kuhlmann D., et al. Toxic effects of desoxycorticosterone esters in dogs. Science 1939, 90(2343):496-497.
55. Lai M., et al. Forebrain mineralocorticoid receptor overexpression enhances memory, reduces anxiety and attenuates neuronal loss in cerebral ischaemia. Eur. J. NeuroSci. 2007, 25(6):1832-1842.
56. Lalevee N., et al. Aldosterone increases T-type calcium channel expression and in vitro beating frequency in neonatal rat cardiomyocytes. Cardiovasc. Res. 2005, 67(2):216-224.
57. Landmesser U., et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J. Clin. Invest. 2003, 111(8):1201-1209.
58. Laursen J.B., et al. Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation 2001, 103(9):1282-1288.
59. Leaf A., Anderson J., Page L.B. Active sodium transport by the isolated toad bladder. J. Gen. Physiol. 1958, 41(4):657-668.
60. Lemarie C.A., Paradis P., Schiffrin E.L. New insights on signaling cascades induced by cross-talk between angiotensin II and aldosterone. J. Mol. Med. 2008, 86(6):673-678.
61. Leopold J.A., et al. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat. Med. 2007, 13(2):189-197.
62. Li L., et al. Endothelin-1 increases vascular superoxide via endothelin(A)-NADPH oxidase pathway in low-renin hypertension. Circulation 2003, 107(7):1053-1058.
63. Lother A., et al. Ablation of mineralocorticoid receptors in myocytes but not in fibroblasts preserves cardiac function. Hypertension 2011, 57(4):746-754.
64. MacLeod A.B., Vasdev S., Smeda J.S. The role of blood pressure and aldosterone in the production of hemorrhagic stroke in captopril-treated hypertensive rats. Stroke 1997, 28(9):1821-1828. discussion 1829.
65. Marchesi C., Paradis P., Schiffrin E.L. Role of the renin-angiotensin system in vascular inflammation. Trends Pharmacol. Sci. 2008, 29(7):367-374.
66. Mazak I., et al. Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells. Circulation 2004, 109(22):2792-2800.
67. Meyer W.J., Nichols N.R. Mineralocorticoid binding in cultured smooth muscle cells and fibroblasts from rat aorta. J. Steroid. Biochem. 1981, 14(11):1157-1168.
68. Mihailidou A.S., et al. Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Hypertension 2009, 54(6):1306-1312.
69. Milliez P., et al. Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. Eur. Heart J. 2005, 26(20):2193-2199.
70. Milliez P., et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J. Am. Coll. Cardiol. 2005, 45(8):1243-1248.
71. Min L.J., et al. Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells. Circ. Res. 2005, 97(5):434-442.
72. Mollnau H., et al. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ. Res. 2002, 90(4):E58-E65.
73. Myles K., Funder J.W. Progesterone binding to mineralocorticoid receptors: in vitro and in vivo studies. Am. J. Physiol. 1996, 270(4 Pt 1):E601-E607.
74. Naito M., et al. Macrophage differentiation and granulomatous inflammation in osteopetrotic mice (op/op) defective in the production of CSF-1. Mol. Reprod. Dev. 1997, 46(1):85-91.
75. Nishimura H., et al. Mineralocorticoid receptor blockade ameliorates peritoneal fibrosis in new rat peritonitis model. Am. J. Physiol. Renal. Physiol. 2008, 294(5):F1084-F1093.
76. Nishiyama A., et al. Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. Hypertension 2004, 43(4):841-848.
77. Oestreicher E.M., et al. Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-l-arginine methyl ester-induced myocardial injury. Circulation 2003, 108(20):2517-2523.
78. Ouvrard-Pascaud A., et al. Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation 2005, 111(23):3025-3033.
79. Park J.B., Schiffrin E.L. Small artery remodeling is the most prevalent (earliest?) form of target organ damage in mild essential hypertension. J. Hypertens. 2001, 19(5):921-930.
80. Park Y.M., et al. NAD(P)H oxidase inhibitor prevents blood pressure elevation and cardiovascular hypertrophy in aldosterone-infused rats. Biochem. Biophys. Res. Commun. 2004, 313(3):812-817.
81. Park Y.M., et al. Expression of NAD(P)H oxidase subunits and their contribution to cardiovascular damage in aldosterone/salt-induced hypertensive rat. J. Korean Med. Sci. 2008, 23(6):1039-1045.
82. Pearce P., Funder J.W. High affinity aldosterone binding sites (type I receptors) in rat heart. Clin. Exp. Pharmacol. Physiol. 1987, 14(11-12):859-866.
83. Persy V.P., et al. Reduced postischemic macrophage infiltration and interstitial fibrosis in osteopontin knockout mice. Kidney Int. 2003, 63(2):543-553.
84. Pitt B., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N. Engl. J. Med. 1999, 341(10):709-717.
85. Pitt B., et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003, 108(15):1831-1838.
86. Pitt B., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 2003, 348(14):1309-1321.
87. Qin W., et al. Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ. Res. 2003, 93(1):69-76.
88. Ratajska A., et al. Angiotensin II associated cardiac myocyte necrosis: role of adrenal catecholamines. Cardiovasc. Res. 1994, 28(5):684-690.
89. Ratajska A., et al. Angiotensin II and structural remodeling of coronary vessels in rats. J. Lab. Clin. Med. 1994, 124(3):408-415.
90. Rickard A.J., et al. Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure. Hypertension 2009, 54(3):537-543.
91. Robert V., et al. Increased cardiac types I and III collagen mRNAs in aldosterone-salt hypertension. Hypertension 1994, 24(1):30-36.
92. Robert V., et al. Biological determinants of aldosterone-induced cardiac fibrosis in rats. Hypertension 1995, 26(6 Pt 1):971-978.
93. Robert V., et al. Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis. Hypertension 1999, 33(4):981-986.
94. Rocha R., Funder J.W. The pathophysiology of aldosterone in the cardiovascular system. Ann. NY Acad. Sci. 2002, 970:89-100.
95. Rocha R., et al. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998, 31(1 Pt 2):451-458.
96. Rocha R., et al. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 1999, 33(1 Pt 2):232-237.
97. Rocha R., et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000, 141(10):3871-3878.
98. Rocha R., et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am. J. Physiol. Heart Circ. Physiol. 2002, 283(5):H1802-H1810.
99. Rocha R., et al. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 2002, 143(12):4828-4836.
100. Rossier M.F., et al. Corticosteroids and redox potential modulate spontaneous contractions in isolated rat ventricular cardiomyocytes. Hypertension 2008, 52(4):721-728.
101. Rougier J.S., et al. Mineralocorticoid receptor is essential for corticosteroid-induced up-regulation of l-type calcium currents in cultured neonatal cardiomyocytes. Pflugers Arch. 2008, 456(2):407-412.
102. Rozeboom A.M., Akil H., Seasholtz A.F. Mineralocorticoid receptor overexpression in forebrain decreases anxiety-like behavior and alters the stress response in mice. Proc. Natl. Acad. Sci. USA 2007, 104(11):4688-4693.
103. Rude M.K., et al. Aldosterone stimulates matrix metalloproteinases and reactive oxygen species in adult rat ventricular cardiomyocytes. Hypertension 2005, 46(3):555-561.
104. Sato A., Funder J.W. High glucose stimulates aldosterone-induced hypertrophy via type I mineralocorticoid receptors in neonatal rat cardiomyocytes. Endocrinology 1996, 137(10):4145-4153.
105. Schiffrin E.L., Franks D.J., Gutkowska J. Effect of aldosterone on vascular angiotensin II receptors in the rat. Can. J. Physiol. Pharmacol. 1985, 63(12):1522-1527.
106. Selye H. The general adaptation syndrome and the diseases of adaptation. J. Allergy 1946, 17(6). pp. 231, 289, 358.
107. Smith R.E., et al. Vascular localization of the 11 beta-hydroxysteroid dehydrogenase type II enzyme. Clin. Exp. Pharmacol. Physiol. 1996, 23(6-7):549-551.
108. Stas S., et al. Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling. Endocrinology 2007, 148(8):3773-3780.
109. Sugiyama T., et al. Aldosterone induces angiotensin converting enzyme gene expression via a JAK2-dependent pathway in rat endothelial cells. Endocrinology 2005, 146(9):3900-3906.
110. Sun Y., Weber K.T. Angiotensin II and aldosterone receptor binding in rat heart and kidney: response to chronic angiotensin II or aldosterone administration. J. Lab. Clin. Med. 1993, 122(4):404-411.
111. Sun Y., Ratajska A., Weber K.T. Inhibition of angiotensin-converting enzyme and attenuation of myocardial fibrosis by lisinopril in rats receiving angiotensin II. J. Lab. Clin. Med. 1995, 126(1):95-101.
112. Sun Y., et al. Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am. J. Pathol. 2002, 161(5):1773-1781.
113. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol. Rev. 1999, 79(1):215-262.
114. Taddei S., et al. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation 1998, 97(22):2222-2229.
115. Tait S.A., Tait J.F. The correspondence of S.A.S. Simpson and J.F. Tait with T. Reichstein during their collaborative work on the isolation and elucidation of the structure of electrocortin (later aldosterone). Steroids 1998, 63(9):440-453.
116. Tanaka K., et al. Aldosterone induces circadian gene expression of clock genes in H9c2 cardiomyoblasts. Heart Vessels 2007, 22(4):254-260.
117. Turchin A., et al. Effect of acute aldosterone administration on gene expression profile in the heart. Endocrinology 2006, 147(7):3183-3189.
118. Ullian M.E., Schelling J.R., Linas S.L. Aldosterone enhances angiotensin II receptor binding and inositol phosphate responses. Hypertension 1992, 20(1):67-73.
119. Usher, M.G., et al. Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J. Clin. Invest. 120(9), 3350-3364.
120. Virdis A., et al. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 2002, 40(4):504-510.
121. Ward M.R., et al. Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries. Circulation 2001, 104(4):467-472.
122. Weber K.T. Cardiac interstitium in health and disease: the fibrillar collagen network. J. Am. Coll. Cardiol. 1989, 13(7):1637-1652.
123. Weber K.T., Brilla C.G., Janicki J.S. Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc. Res. 1993, 27(3):341-348.
124. Wilson P., et al. Mediators of mineralocorticoid receptor-induced profibrotic inflammatory responses in the heart. Clin. Sci. (Lond.) 2009, 116(9):731-739.
125. Wong S., et al. A direct effect of aldosterone on endothelin-1 gene expression in vivo. Endocrinology 2007, 148(4):1511-1517.
126. Wynn T.A. Cellular and molecular mechanisms of fibrosis. J. Pathol. 2008, 214(2):199-210.
127. Xiao F., Puddefoot J.R., Vinson G.P. Aldosterone mediates angiotensin II-stimulated rat vascular smooth muscle cell proliferation. J. Endocrinol. 2000, 165(2):533-536.
128. Young M.J., Funder J.W. The renin-angiotensin-aldosterone system in experimental mineralocorticoid-salt-induced cardiac fibrosis. Am. J. Physiol. 1996, 271(5 Pt 1):E883-E888.
129. Young M., Funder J.W. Eplerenone, but not steroid withdrawal, reverses cardiac fibrosis in deoxycorticosterone/salt-treated rats. Endocrinology 2004, 145(7):3153-3157.
130. Young M., et al. Mineralocorticoids, hypertension, and cardiac fibrosis. J. Clin. Invest. 1994, 93(6):2578-2583.
131. Young M., Head G., Funder J. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am. J. Physiol. 1995, 269(4 Pt 1):E657-E662.
132. Young M.J., et al. Early inflammatory responses in experimental cardiac hypertrophy and fibrosis: effects of 11 beta-hydroxysteroid dehydrogenase inactivation. Endocrinology 2003, 144(3):1121-1125.